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Abstract
Background: Youth who are being treated with antipsychotic medications are at increased risk for the development of obesity
and type 2 diabetes. Behavioral weight loss treatments show promise for reducing obesity and diabetes risk among adults
treated with these drugs, but such treatments have not previously been studied in youth.
Objective: We describe a rationale for behavioral weight loss intervention for high-weight youth being treated with
antipsychotic medications. We report behavioral, anthropomorphic, and metabolic findings from a case series of obese
adolescents taking antipsychotic medications who participated in a short-term, family-based behavioral weight loss
intervention.
Methods: We adapted the Traffic Light Plan, a 16-week family-based weight loss intervention that promotes healthy energy
balance using the colors of the traffic light to categorize the nutritional value of foods and the intensity of physical activity.
We then added a social and ecological framework to address health behavior change in multiple social contexts. The
intervention was administered to three obese adolescents with long-term antipsychotic medication exposure. The efficacy of
the intervention was evaluated with a battery of anthropomorphic and metabolic assessments, including weight, body mass
index percentile, whole body adiposity, liver fat content, and fasting plasma glucose and lipid levels. Participants and their
parents also filled out a treatment satisfaction questionnaire after study completion.
Results: Two boys and one girl, all of whom were 14 years old, participated in this study. All three participants attended all
16 sessions of the intervention and experienced beneficial changes in adiposity, fasting lipid levels, and liver fat content
associated with weight stabilization or weight loss. Adolescents and their parents all reported a high level of satisfaction with
the treatment.
Conclusions: Family-based behavioral weight loss treatment can be feasibly delivered and is acceptable to youth taking
antipsychotic medications and their families. Randomized controlled trials are needed to fully evaluate the effectiveness and
acceptability of these treatments for these individuals.

ClinicalTrials.gov Identifier: NCT01222494
Keywords: pediatric obesity; antipsychotics; at-risk youth; weight loss treatment
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Introduction
Pediatric obesity is a rising public health concern that
is associated with the early onset of cardiovascular
disease risk conditions such as fatty liver and diabetes
(1-3). Children with psychiatric conditions may be
particularly vulnerable to the development of obesity
and related adverse health conditions (4). The
increased risk for obesity in psychiatric populations
is exacerbated by the use of second-generation
antipsychotic medications (hereafter referred to as
antipsychotics), which increase the risk for weight gain
and related adverse changes in lipid and glucose
metabolism (5,6). Youth who are being treated with
antipsychotics are more than twice as likely as
children in the general population to develop obesityrelated cardiometabolic risk conditions like diabetes,
hypertension, and hyperlipidemia (7-9). For
populations in which obesity is the result of medical
treatments, first-line treatment strategies include the
discontinuation of agents that cause or contribute to
weight gain and substitution with a lower-risk agent
if one is available (10; p. 2489). Although
antipsychotic discontinuation in youth is associated
with weight loss, it may come at the price of
psychiatric symptom recurrence, including aggressive
or self-injurious behavior (11-13). Therefore, it is
imperative to identify strategies to mitigate weight
gain
when
maintenance
treatment
with
antipsychotics is necessary.
The putative mechanisms of antipsychotic-induced
weight gain are related to the medications’
combination of dopamine blockade at D2 receptors,
antagonism or inverse agonism at 5HT2C serotonin
receptors, antagonism at 5HT2A serotonin receptors,
antagonism at alpha-1A adrenergic receptors, and
especially antagonism at histamine-1 receptors (14).
Blocking the activity of dopamine—particularly in
the subcortical, limbic, and striatal areas of the
brain—leads to an upregulation of postsynaptic
receptors as well as increased dopamine within the
synaptic cleft, which may create a “reward
deficiency” syndrome that prevents satiety (15).
Serotonin receptor inverse agonism or antagonism
may lead to decreased satiety and hyperphagia
(16,17). Finally, weight gain has long been associated
with centrally active drugs that have high affinity for
the histamine-1 receptor, and H1 antagonism is
known to increase feeding (18,19) and sedation, with
predictable reductions in caloric expenditure (14).
Although treatment-related weight gain is
pharmacologically driven, it could potentially be
addressed by behavioral strategies that affect
decreased satiety, increased food seeking, and
sedentary behavior. Core principles of behavioral
weight loss that may impact satiety and activity level
typically involve food and activity substitutions, with

progressive goal setting and reinforcement to reach
the identified terminal health behavior targets and to
change food and activity preferences.
Intensive behavioral weight loss and lifestyle
modification programs have been successfully
adapted for use in adults with psychotic disorders and
other severe mental illnesses who are taking
antipsychotics (20-22). One particularly successful
weight loss intervention has incorporated
psychosocial and cognitive rehabilitation strategies
into a health education framework in a setting in
which patients received mental health care and social
support (23)). Social ecological approaches to health
behavior change in psychiatric populations consider
the adjustment, coping, and adaptive functioning of
the individual within a social and cultural context
(24). This focus on facilitating the individual’s
involvement in and impact on the environment as an
agent of change is thought to enhance the likelihood
of the sustained improvement of health behaviors.
Social ecological models of pediatric health behavior
change include the family as an integral part of the
child’s immediate environment and promote the
development of parent-facilitated social networks
that support health behavior change and that address
social barriers to engaging in health behavior change
(25,26). Weight loss treatments that make use of a
social ecological approach to health behavior change
may be ideally suited to promoting health behavior
change in mentally ill youth, because psychosocial
barriers to participation may be more pronounced as
compared with populations of non-psychiatrically ill
individuals. Family is part of the first and perhaps
most important layer of social ecology in the lives of
children, and thus social ecological approaches that
focus on the involvement of social supports,
including family, may be of primary importance for
individuals who face psychiatric illnesses as barriers
to health behavior change.
Family-based behavioral weight loss treatment
(FBT) is considered a first-line treatment for the
management of pediatric obesity (27,28). Published
meta-analyses have documented that such
interventions lead to improved weight outcomes
among children and adolescents (29,30). However,
these reports also highlight the need for studies that
evaluate treatment-related changes in metabolic
parameters and that test strategies for enhancing realworld intervention delivery, particularly in at-risk
populations such as individuals with psychiatric
illnesses who are treated with antipsychotics (31). To
our knowledge, two studies that included behavioral
weight loss as part of the study design have been
conducted in overweight or obese youth treated with
antipsychotics (32,33). However, we are aware of no
published studies evaluating the feasibility and
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efficacy of family-based behavioral weight loss
interventions in this population nor of any studies
that measure the impact of such interventions on
metabolic health outcomes.
The present report describes a modified FBT
approach to weight loss among youth taking
antipsychotics and reports on the first three
participants in a randomized controlled trial to
evaluate the efficacy of FBT for weight loss in youth
between the ages of 6 and 18 years treated with
antipsychotics. The design of this study involves
delivering weekly FBT to youth with psychiatric
illnesses treated with antipsychotics as compared
with otherwise healthy but overweight or obese
youth, with a monthly standard-of-care reference
group treated with antipsychotics. The primary
outcomes of this study include gold-standard
measures of body composition and metabolism:
changes in total percentage of body fat and liver fat,
measured respectively via dual energy X-ray
absorptiometry
and
magnetic
resonance
spectroscopy; common clinical measures, such as
body mass index (BMI) and BMI percentile; vital
signs; and fasting plasma lipid and glucose values. We
hypothesize that individuals treated with
antipsychotic agents can successfully participate in
behavioral weight loss treatment without adverse
weight or metabolic outcomes. Here, we describe the
weekly FBT program adapted for use in youth treated
with antipsychotics to incorporate a social ecological
approach, and we report changes in weight and other
measures of metabolic health in the initial three
patients who completed the weight loss treatment.

5)

6)
7)

evidence of psychiatric stability (i.e., no
inpatient hospitalizations during the previous
6 months and no changes in psychotropic
medication doses for 4 weeks);
consenting adult caregiver willing to
participate in the study; and
ability to provide assent for participation as
evidenced by documented or clinically
estimated intelligence quotient of 70 or higher.

Exclusion criteria included the following:
1) youth who were not overweight or obese by
BMI percentile;
2) age outside the specified range of 6 to 18 years;
3) no presence of any Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, Text
Revision diagnosis;
4) less than 6 months of antipsychotic treatment;
5) active suicidality or substance use disorders;
6) lack of psychiatrically stability and/or
antipsychotic
treatment
deemed
inappropriate;
7) no consenting adult caregiver able to
participate in the study; and
8) estimated or documented intelligence quotient
of less than 70.
Concurrent treatment with selective serotonin
reuptake
inhibitors
and
attention-deficit/
hyperactivity disorder medications (including
stimulants, Atomoxetine, or alpha-agonist agents
below a total daily dose of 2 mg/kg methylphenidate
equivalent) was permitted to increase the
generalizability of results. A large portion of youth
treated with antipsychotics are concurrently treated
with selective serotonin reuptake inhibitors,
stimulants, and other psychotropic medications (34).
More specifically, the use of antipsychotics for
treatment-resistant attention-deficit/hyperactivity
disorder is increasingly common (35).

Participants

Three adolescent participants were recruited from
the Washington University School of Medicine Child
and Adolescent Psychiatry Outpatient Clinic. In all
cases, the participant’s pediatrician or primary care
provider was notified of study participation and
provided medical assent. Outpatient weights and
heights collected during the year prior to study
enrollment were obtained for all participants from
their primary care provider or treating psychiatrist.
Inclusion criteria for the overall study included the
following:
1) overweight (BMI percentile ≥85) or obese
(BMI percentile ≥95) youth between the ages
of 6 and 18 years;
2) any Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition, Text Revision diagnosis;
3) at least 6 continuous months of treatment
with antipsychotics;
4) documented weight gain that was greater than
expected (e.g., crossing a percentile line on the
BMI growth chart);

Study Assessments

Participants were youth between the ages of 6 and18
years who were enrolled in the National Institute of
Mental Health–funded “Measurement of Cardiometabolic Risk in Antipsychotic Treated Youth”
study. This is a randomized controlled trial to
evaluate metabolic changes in overweight or obese
youth treated with antipsychotics during behavioral
weight loss treatment as compared with obese or
overweight but otherwise healthy controls
undergoing the same behavioral weight loss
treatment. All participants underwent a clinical
evaluation by a study psychiatrist to ensure
psychiatric stability and the appropriateness of
continued antipsychotic treatment during study
participation. Diagnoses were based on Diagnostic and
98
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Statistical Manual of Mental Disorders, Fourth Edition,
Text Revision criteria and corroborated with records
of previous psychiatric treatment. A consensus study
diagnosis was based on the preponderance of clinical
and study data. Baseline assessments were conducted
within one month of study enrollment, and endpoint
assessments were conducted within two weeks of
completing the 16-week weight loss treatment. All
blood draws and physical study assessments were
performed at the Washington University Pediatric
Research Unit; imaging was performed at the Center
for Clinical Imaging in Research and at the Nutrition
Obesity Research Center and included the following:
height and weight measurements performed on a
calibrated stadiometer (Seca 240 Wall-Mounted
Stadiometer, Germany) and scale (Seca 684 Digital
Multifunctional Scale, Germany), respectively, by a
trained research nurse whole body fat percentage
measured using dual energy X-ray absorptiometry
(Delphi W densitometer equipped with version 12.4
software; Hologic, Waltham, MA); intrahepatic
triglyceride content determined at baseline and at the
study endpoint by proton magnetic resonance
spectroscopy with a 1.5 T scanner (Magnetom
Sonata; Seimens, Erlangen, Germany), with all
frequencies (i.e., chemical shifts) measured relative to
the principal water 1H resonance; and fasting plasma
lipid (i.e., total cholesterol, low density lipoprotein
cholesterol, high density lipoprotein cholesterol, and
triglyceride) and glucose levels. Weekly treatment
weights were measured on a digital office-based scale
(Health o meter, Sunbeam Products Inc., Boca
Raton, FL). BMI, BMI percentile, and BMI Z-score
were calculated from medical records for each
subject at 12 and 6 months prior to study enrollment
and at the baseline and endpoint study assessments.
The Washington University in St. Louis Institutional
Review Board approved this study.

year during the prepubertal and pubertal growth
stages, with weight gain being higher in prepubertal
females as compared with males and higher in
pubertal males as compared with females (39,40). For
individuals who are already at a high weight, the
range of 0.5 to 2 lb per week is a safe weight loss
range for all ages and stages of growth. Core
components of behavioral weight loss strategies
include education about energy balance, shaping
behaviors to promote stimulus control, and selfmonitoring. The Traffic Light Plan is used as a
framework to help families shift their energy intake
and expenditure with the use of a classification
system in which the nutritional values of foods and
the intensity values of activities are coded as RED for
“stop and think” to indicate the least healthy options,
YELLOW for “caution” to indicate moderately
healthy options, and GREEN for “go” to indicate
the healthiest options (41-44). Both participating
parents and youths are asked to self-monitor their
daily food intake and physical activity. Youth and
their participating parents are asked to select from a
list of behavioral rewards (which exclude options
related to food or sedentary behavior) for
accumulating points when weekly goals are met.
Child and parent weights are measured during each
in-person session.
In the present case series, modifications were made
to the existing FBT framework to facilitate delivery
in an outpatient psychiatric treatment setting. First,
we removed the weekly group meeting and increased
contact with the treatment team through a mid-week
phone check-in, and we incorporated the group
content and skills practice into the individual family
sessions. This was done to reduce the total time spent
in person per week by families and interventionists
and to allow interventionists to provide support and
reminders to engage in self-monitoring and health
behavior changes throughout the week. We also
employed a simplified, one-page food and activity log
composed of visual cues for RED and GREEN
foods and activities. This was done to simplify food
logging for youth who had learning disabilities or
other cognitive challenges. We created and used a
“taste log” to incentivize trying new GREEN and
YELLOW foods and to promote serial
desensitization for youth with food aversions or
selective eating patterns. In addition, we included an
ecological-based social facilitation component in
each session to encourage the consolidation of health
behavior changes across environmental contexts; we
took into account the developmental stage of the
participating youth, and we encouraged parents to
facilitate the development and use of peer and
community networks to support health behavior
change. Weekly treatment goals were divided into
energy balance, weight loss, and social facilitation

Treatment Description

FBT is an evidence-based intervention that consists
of weekly sessions for 12 to 24 weeks and that
includes individual family member weigh-ins,
meetings with a trained interventionist, and separate
parent and child groups (36). FBT targets family
support and restructuring of the home environment
to enable healthier behaviors while establishing selfregulatory behaviors to promote weight management. A weight loss goal range of 0.5 to 2 lb per week
is set for both participating children and adults; this
range is in line with evidence-based childhood
obesity treatment (37) and recommenddations for
healthy child development and weight management
/27,38). Expected annual weight gain during normal
growth and development varies on the basis of age
and gender and can range from 2 to 3 lb per year in
prepubertal and postpubertal youth to 8 to 12 lb per
99
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domains, and target ranges for scaled goal attainment
were created within each domain. This allowed the
interventionist to individualize weekly goals on the
basis of child- and family-level characteristics and
needs.

measurable improvements in portions of the lipid
panel and in liver fat content. Finally, each of the
three cases involved a parenting component that
challenged the family’s ability to maintain a healthy
weight, which suggests that a family-based approach
may be useful in this population to support parents
who want to help their children make health behavior
changes (Table 1).
There are important limitations to note. As a case
series, the sample of participants reported here was
small and warrants continued evaluation, because the
results may not be representative of the general
population of children with psychiatric conditions
who are overweight or obese. Moreover, these
participants were adolescents, and our larger trial
addresses both children and adolescents between the
ages of 6 to 18 years. Estimates of children’s height
growth patterns can be used to anticipate the weightfor-height changes needed to achieve normal weight
status and to guide weight loss targets on the basis of
a youth’s age- and sex-specific BMI percentiles
(45,46). It is important to note that our presented
cases are adolescents with BMIs above the 99th
percentile for age and gender at entry; children who
are younger and closer to the 85th BMI percentile
need to lose less weight to normalize their BMI
percentiles as compared with youth who are older
and who have a higher degree of obesity (46). Thus,
the expansion of our sample to younger children
across BMI percentiles in the overweight and obese
ranges may provide additional information about
treatment response and may indicate whether
treatment for this population, which is at risk for
continued weight gain, warrants additional
adaptation (e.g., whether weight maintenance is more
appropriate than weight loss for certain
populations)(27,38,46). In addition, there may be
important differences in an individual’s response to
these interventions as a result of gender, ethnicity,
age, and sociodemographic variables that are not
represented by the individuals discussed in this case
series.
Selection bias can confound results in studies of
behavior change: individuals who participate in
research studies may be more motivated than those
in the general population to make health behavior
changes. Participant 1 is an example of this and may
be quite representative of individuals with mild
autism who also have symptoms of attentiondeficit/hyperactivity disorder; these individuals are
commonly treated with a combination of stimulant
and antipsychotic therapy. Although it could be
argued that Participant 1 lost weight before starting
the FBT as a result of concurrent stimulant therapy,
which has a known anorectic effect, stimulants have
not been associated with significant weight loss
among individuals taking antipsychotics (47,48).

Results
Table 1 presents each of the three cases in detail.
Common characteristics among participants
included age, race, and weight related medical
comorbidities (e.g., dyslipidemia, impaired fasting
glucose). Additionally, each case presented unique
parenting challenges related to either parental or
child psychiatric considerations. Quantitative
cardiometabolic outcomes are presented in Table 2.
Beneficial changes in fasting total cholesterol, low
density lipoprotein cholesterol, adiposity, and liver
fat content were documented for Participant 1 and
Participant 3, who both experienced greater changes
in BMI percentile and Z-score as compared with
Participant 2. All participants experienced a slowing
of weight gain as compared with their pretreatment
weight trajectories (Figure 1). No clinically significant
changes in fasting glucose and triglyceride values
were found. Participating parents and youth reported
that they were either “very satisfied” (n = 2) or
“somewhat satisfied” (n = 1) with the treatment
program at study completion. Two parents reported
that they would not suggest any changes to the
treatment; one parent suggested the use of a
computer or mobile device application for
homework and self-monitoring.
Conclusions
Children with mental health conditions—especially
those who are treated with antipsychotics—are
vulnerable to developing obesity and related health
problems. Little research has been conducted
regarding weight loss interventions in this
population. FBT interventions are low risk and are
considered first-line treatments for pediatric obesity,
with evidence for long-term sustainability (36). The
preliminary results reported here represent, to our
knowledge, the first reported for a behavioral weight
loss intervention adapted for use in youth treated
with antipsychotics.
The primary goal of this pilot study was to
demonstrate the feasibility of delivering a behavioral
weight loss treatment to families of youth with
psychiatric conditions. All participants experienced a
beneficial change in or stabilization of their BMI
percentile and Z-score as compared with
pretreatment conditions, and these changes are
similar to those of previous FBT studies (25).
Although greater weight loss was associated with
greater changes in metabolic parameters, it is notable
that small reductions in weight were associated with
100
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TABLE 1. Participant Characteristics and Case Description
Participant 1 was a 14-year-old Caucasian male diagnosed with PDD-NOS1 and ADHD,2 combined type, and Learning Disorder (Reading
and Written Expression). He had received psychiatric treatment since age 5, and at study enrollment was taking atomoxetine (Strattera)
100 mg daily, paroxetine (Paxil) 10 mg daily and risperidone (Risperdal) 3 mg daily. Medical comorbidities related to obesity included
impaired fasting glucose.4 Prior to study participation, food limits being set in the home resulted in aggressive behavioral outbursts.
Treatment was tailored as follows:

To address parent modeling of responsive and assertive communication skills, the therapist worked with parents on how
to identify and anticipate behavioral triggers prior to setting limits and boundaries.

To address difficulties with recording foods related to learning disorder, daily family check-ins allowed the participant to
narrate or dictate food intake to the participating parent, while the youth utilized Traffic Light Plan materials to identify
nutrition data for each food item.
Participant 2 was a 14-year-old Caucasian female diagnosed with Mood Disorder Not Otherwise Specified and GAD.3 She had received
psychiatric treatment since age 7, and at study enrollment was taking quetiapine (Seroquel) 100 mg twice daily and 200 mg at bedtime;
sertraline (Zoloft) 150 mg daily. Medical comorbidity related to obesity included hypercholesterolemia.5 Parental health problems,
including limited mobility and mild cognitive impairment impacted the ability to perform key parenting skills (e.g., regular grocery
shopping, help with completing self-monitoring logs, facilitation of conversations to promote healthy behaviors at home and with peers).
Treatment was tailored as follows:

To reduce cognitive load, handouts incorporating visual cues and simplified messages regarding the primary message in
each meeting were utilized to reinforce session content, and the one-page food and activity log was introduced to simplify
self-monitoring.

To address parental difficulties and communication challenges, the therapists modeled adaptive communication strategies
and provided cues for collaborative problem solving.
Participant 3 was a 14-year-old Caucasian male diagnosed with PDD-NOS1 and ADHD,2 combined type. He had received psychiatric
treatment since age 3, and at study enrollment was taking osmotic-release oral system (OROS)-methylphenidate (Concerta) 54 mg daily,
quetiapine (Seroquel) 150 mg twice daily and 100 mg at bedtime and paroxetine (Paxil) 15 mg daily. Medical comorbidity related to
obesity included dyslipidemia.5 This youth began treatment with a significant preference for RED foods, and taste aversion to most
GREEN foods. Parents reported weight had gradually become a problem over time because their child had limited taste preferences and
became severely agitated when new foods were introduced. Treatment was tailored as follows:

To address distress about trying new foods related to sensory aversion, the interventionist worked with the family on
communication strategies and provided support and education about distress tolerance for parents and youth.

To engage the youth both during the session and during the week at home and school, a focus of therapy became
rewarding attempts to try new GREEN foods using the taste log.
1 Pervasive

Developmental Disorder Not Otherwise Specified
Attention Deficit-Hyperactivity Disorder
3 Generalized Anxiety Disorder
4 Defined by American Diabetes Association Criteria (33)
5 Defined by NCEP Expert Panel on Blood Cholesterol Levels in Children and Adolescents (34)
2

TABLE 2. Changes in Metabolic Health During Study Participation
Participant 1

Participant 2

Participant 3

Mean

Baseline

Endpoint

Baseline

Endpoint

Baseline

Endpoint

Change (SD)

Weight (lbs)

165.6

153.7

270.1

268.7

141.8

141.5

-4.53 (6.40)

BMI %ile

91.13

80.94

99.48

99.41

96.16

92.69

-4.58 (5.15)

BMI z-score

1.35

0.88

2.56

2.52

1.77

1.45

-0.28 (0.22)

Fasting Glucose (mg/dL)

103

93

87

86

97

97

-3.67 (5.51)

Fasting Total Cholesterol (mg/dL)

166

145

209

239

160

139

-4.00 (29.44)

Fasting HDL Cholesterol (mg/dL)

57

62

56

60

41

38

2 (4.36)

Fasting Triglycerides (mg/dL)

59

63

93

106

128

70

-13.67 (38.66)

Fasting LDL Cholesterol (mg/dL)

97

70

134

158

93

87

-3 (25.63)

DEXA Total Percent Fat

28.4

24.2

46.9

48.4

35.6

28.6

-3.23 (4.33)

Percent Liver Fat

2.08

0.62

1.92

2.76

3.54

1.31

-0.95 (1.60)
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FIGURE 1. Participant Weight Trajectories, 1 year Pre-Treatment and During Treatment
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A more likely cause of weight loss before beginning
treatment is the motivation for behavioral change.
After observing the pretreatment weight trajectory
for Participant 1, we modified our study timeline to
allow only 2 weeks between baseline testing and
starting FBT. Finally, although the potential
mechanisms of antipsychotic-related weight gain can
be surmised from receptor binding profiles, future
studies should evaluate the neurobiological changes
associated with antipsychotic treatment and weight
loss treatment to develop more effective and
individualized weight loss interventions.
Clinical Significance
Our findings demonstrates that a minimally modified
FBT intervention can be feasibly delivered to youth
with psychiatric disorders and could be disseminated
via clinical settings in which weekly encounters with
behavioral health providers can occur (e.g.,
community mental health centers). Although
beneficial changes were noted in liver fat, whole body
adiposity, fasting total cholesterol, and low density
lipoprotein cholesterol levels, definitive conclusions
regarding the effectiveness of this intervention
cannot be made on the basis of the results of these
first three participants. Further study is needed to
more definitively determine treatment effectiveness,
to clearly identify population- and diagnosis-specific
challenges to weight loss, and to determine the most
effective strategies for personalizing treatment and
mobilizing family member support to promote
weight loss success.
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